Learn key verification steps, FDA guidelines, and risks to protect your health with expert-backed information
Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial
At the end of treatment, average weight losses were 11.8% in the 75 mg once-daily weekly-titration group and 11.1% in the 75 mg once-daily every-2-week titration group
Inside the Polarizing Debate 03:41 UP NEXT FDA Advisory Panel Votes to Loosen Peptide Restrictions 00:35 Things Drivers Do That Are More Likely to Get Them a Traffic Ticket 05:05 Why Bear Encounters Are Soaring Across the US 02:10 Exclusive: Purdue Set to Launch Amelia Earhart Search Expedition 03:03 A Combined $1.3B is Up for Grabs in Mega Millions and Powerball 02:02 Inside Costcos Growing 'Cool Factor' With Younger Shoppers 03:19 All 11 Passengers Rescued After Fiery Seaplane Crash 02:12 Real-Life 'Spider-Man' Helps Man in Wheelchair to Safety 01:04 Outrage Boils Over in Fatal Police Shooting of Man in Wisconsin 02:23 White House Correspondents Dinner Returns Under High Security 02:28 Trump Vows Retaliation Against Iran for Houthi Attack in Red Sea 05:08 Tropical Storm Bertha Makes 2nd Landfall

Women are more willing to tolerate injections for weight loss Women were more likely than men to say they would tolerate injections for weight loss despite disliking needles, at 11.23% compared to 7.94%
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the gut after eating